Distinguished in Rheumatoid Arthritis (RA)

Dr. Jeffrey S. Carlin

Rheumatology
The Association Of University Physicians
1959 Ne Pacific St, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
Distinguished in Rheumatoid Arthritis (RA)
The Association Of University Physicians
1959 Ne Pacific St, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeffrey Carlin is a Rheumatologist in Seattle, Washington. Dr. Carlin is rated as a Distinguished provider by MediFind in the treatment of Rheumatoid Arthritis (RA). His top areas of expertise are Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA), Scleroma, and Scleroderma. Dr. Carlin is currently accepting new patients.

His clinical research consists of co-authoring 8 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles and participated in 1 clinical trial in the study of Rheumatoid Arthritis (RA).

Specialties
Rheumatology
Licenses
Internal Medicine in WA
Hospital Affiliations
University Of Washington Medical Ctr
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO

Locations

THE ASSOCIATION OF UNIVERSITY PHYSICIANS
1959 Ne Pacific St, Seattle, WA 98195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: Ifetroban
Study Phase: Phase 2
Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis
Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: June 12, 2025
Intervention Type: Drug
Study Drug: Hydroxychloroquine
Study Phase: Phase 2
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Iloprost
Study Phase: Phase 3
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drug: Belumosudil (KD025)
Study Phase: Phase 2
A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Enrollment Status: Terminated
Publish Date: June 05, 2023
Intervention Type: Drug
Study Drug: Belumosudil
Study Phase: Phase 2
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 7 Less Clinical Trials

8 Total Publications

T Cells Promote Distinct Transcriptional Programs of Cutaneous Inflammatory Disease in Keratinocytes and Dermal Fibroblasts.
T Cells Promote Distinct Transcriptional Programs of Cutaneous Inflammatory Disease in Keratinocytes and Dermal Fibroblasts.
Journal: The Journal of investigative dermatology
Published: August 30, 2024
Similar Doctors
Elite in Rheumatoid Arthritis (RA)
Dr. Philip J. Mease
Rheumatology
Elite in Rheumatoid Arthritis (RA)
Dr. Philip J. Mease
Rheumatology
601 Broadway, 
Seattle, WA 
 (3.0 miles away)
206-386-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Philip Mease is a Rheumatologist in Seattle, Washington. Dr. Mease is rated as an Elite provider by MediFind in the treatment of Rheumatoid Arthritis (RA). His top areas of expertise are Psoriatic Arthritis, Arthritis, Psoriasis, and Axial Spondyloarthritis (AxSpA). Dr. Mease is currently accepting new patients.

Elite in Rheumatoid Arthritis (RA)
Dr. Jane H. Buckner
Rheumatology
Elite in Rheumatoid Arthritis (RA)
Dr. Jane H. Buckner
Rheumatology

Virginia Mason Medical Center

4575 Sand Point Way Ne, Suite 108, 
Seattle, WA 
 (1.4 miles away)
206-525-8000
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Jane Buckner is a Rheumatologist in Seattle, Washington. Dr. Buckner is rated as a Distinguished provider by MediFind in the treatment of Rheumatoid Arthritis (RA). Her top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Relapsing Polychondritis, and Systemic Lupus Erythematosus (SLE). Dr. Buckner is currently accepting new patients.

Distinguished in Rheumatoid Arthritis (RA)
Dr. Katherine D. Wysham
Rheumatology
Distinguished in Rheumatoid Arthritis (RA)
Dr. Katherine D. Wysham
Rheumatology
1660 S Columbian Way # 151-a, 
Seattle, WA 
 (6.0 miles away)
206-277-3293
Languages Spoken:
English

Katherine Wysham is a Rheumatologist in Seattle, Washington. Dr. Wysham is rated as a Distinguished provider by MediFind in the treatment of Rheumatoid Arthritis (RA). Her top areas of expertise are Rheumatoid Lung Disease, Rheumatoid Arthritis (RA), Arthritis, Osteoporosis, and Knee Replacement.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Carlin's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 18 Advanced Conditions
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile